Tech Company Financing Transactions
Specific Biologics Funding Round
Specific Biologics, based in Toronto, Ontario, secured investment capital from adMare BioInnovations and Lumira Ventures.
Transaction Overview
Company Name
Announced On
10/16/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
adMare BioInnovations (Lead Investor)
Lumira Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance the preclinical development of therapeutics based on its proprietary Dualase® platform gene editors in liver, ocular and CNS disorders and continue the development of Dualase gene editors for Cystic Fibrosis with preclinical studies supported by the Cystic Fibrosis Foundation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
661 University Avenue, West Towern 1300
Toronto, Ontario, M5G 0B7
CA
Toronto, Ontario, M5G 0B7
CA
Phone
Undisclosed
Website
Email Address
Overview
Specific Biologics develops novel gene editing technologies to treat diseases at the genetic level in cells inside the body.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brent Stead
Chief Operating Officer
Odisho Israel
Browse more venture capital transactions:
Prev: 10/16/2023: Neutral venture capital transaction
Next: 10/16/2023: Xpanceo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs